120 related articles for article (PubMed ID: 9840212)
1. Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers.
Adams MH; Poynor WJ; Garnett WR; Karnes HT; Ferry JJ; Ryan KK; Sarkar MA
Biopharm Drug Dispos; 1998 Nov; 19(8):501-15. PubMed ID: 9840212
[TBL] [Abstract][Full Text] [Related]
2. Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects.
Andersen V; Sonne J; Larsen S
Scand J Gastroenterol; 1999 Aug; 34(8):813-7. PubMed ID: 10499483
[TBL] [Abstract][Full Text] [Related]
3. Hepatic drug clearance in patients with mild cystic fibrosis.
Kearns GL; Crom WR; Karlson KH; Mallory GB; Evans WE
Clin Pharmacol Ther; 1996 May; 59(5):529-40. PubMed ID: 8646824
[TBL] [Abstract][Full Text] [Related]
4. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
[TBL] [Abstract][Full Text] [Related]
5. Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.
Greenblatt DJ; Allen MD; MacLaughlin DS; Huffman DH; Harmatz JS; Shader RI
J Pharmacokinet Biopharm; 1979 Apr; 7(2):159-79. PubMed ID: 20218012
[TBL] [Abstract][Full Text] [Related]
6. Enhanced hepatic drug clearance in patients with cystic fibrosis.
Kearns GL; Mallory GB; Crom WR; Evans WE
J Pediatr; 1990 Dec; 117(6):972-9. PubMed ID: 2246703
[TBL] [Abstract][Full Text] [Related]
7. Effect of neurotrauma on hepatic drug clearance.
Boucher BA; Kuhl DA; Fabian TC; Robertson JT
Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):487-97. PubMed ID: 1934861
[TBL] [Abstract][Full Text] [Related]
8. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
[TBL] [Abstract][Full Text] [Related]
9. The effect of hepatic disease on the disposition of moricizine in humans.
Pieniaszek HJ; Davidson AF; McEntegart CM; Quon CY; Sampliner RE; Mayersohn M
Biopharm Drug Dispos; 1994 Apr; 15(3):243-52. PubMed ID: 7880984
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of 2.5- to 10-mg oral doses of minoxidil in healthy volunteers.
Fleishaker JC; Andreadis NA; Welshman IR; Wright CE
J Clin Pharmacol; 1989 Feb; 29(2):162-7. PubMed ID: 2715373
[TBL] [Abstract][Full Text] [Related]
11. The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine.
Razak TA; McNeil JJ; Sewell RB; Drummer OH; Smallwood RA; Conway EL; Louis WJ
Clin Pharmacol Ther; 1990 Apr; 47(4):463-9. PubMed ID: 2328554
[TBL] [Abstract][Full Text] [Related]
12. Effect of experimental hemorrhagic shock on hepatic drug elimination.
DiPiro JT; Hooker KD; Sherman JC; Gaines MG; Wynn JJ
Crit Care Med; 1992 Jun; 20(6):810-5. PubMed ID: 1597036
[TBL] [Abstract][Full Text] [Related]
13. The effect of halothane on the recirculatory pharmacokinetics of physiologic markers.
Avram MJ; Krejcie TC; Niemann CU; Klein C; Gentry WB; Shanks CA; Henthorn TK
Anesthesiology; 1997 Dec; 87(6):1381-93. PubMed ID: 9416724
[TBL] [Abstract][Full Text] [Related]
14. Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases.
Kawasaki S; Sugiyama Y; Iga T; Hanano M; Beppu T; Sugiura M; Sanjo K; Idezuki Y
Clin Pharmacol Ther; 1988 Aug; 44(2):217-24. PubMed ID: 3396264
[TBL] [Abstract][Full Text] [Related]
15. The effect of zileuton on antipyrine and indocyanine green disposition.
St Peter JV; Braeckman RA; Granneman GR; Locke CS; Cavanaugh JH; Awni WM
Clin Pharmacol Ther; 1995 Mar; 57(3):299-308. PubMed ID: 7697947
[TBL] [Abstract][Full Text] [Related]
16. Beta-adrenergic blockade affects initial drug distribution due to decreased cardiac output and altered blood flow distribution.
Avram MJ; Krejcie TC; Henthorn TK; Niemann CU
J Pharmacol Exp Ther; 2004 Nov; 311(2):617-24. PubMed ID: 15197245
[TBL] [Abstract][Full Text] [Related]
17. Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test.
Saudek F; Morávek J; Modr Z
Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):82-7. PubMed ID: 2921099
[TBL] [Abstract][Full Text] [Related]
18. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.
Figg WD; Dukes GE; Lesesne HR; Carson SW; Songer SS; Pritchard JF; Hermann DJ; Powell JR; Hak LJ
Pharmacotherapy; 1995; 15(6):693-700. PubMed ID: 8602375
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of flecainide in patients with cirrhosis of the liver.
McQuinn RL; Pentikäinen PJ; Chang SF; Conard GJ
Clin Pharmacol Ther; 1988 Nov; 44(5):566-72. PubMed ID: 3141098
[TBL] [Abstract][Full Text] [Related]
20. The effect of acute withdrawal from cigarette smoking on indocyanine green and antipyrine clearance.
Eldon MA; Luecker PW; MacGee J; Ritschel WA
J Clin Pharmacol; 1987 Mar; 27(3):226-32. PubMed ID: 3680579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
